Email this article 
Treatment of central nervous system lymphoma — literature review and own experiences
- Authors: Minenko S.V.1, Larina Y.V.1, Ptushkin V.V.1, Khuazheva N.K.2, Lunin V.V.2, Perestoronina T.N.1, Biyachuev E.R.1, Pshonkin A.V.1, Semochkin S.V.1, Sheikh Z.V.2, Yakovlev V.N.2, Alekseev V.G.2
-
Affiliations:
- Federal Research Center of Pediatric Hematology, Oncology and Immunology
- Botkin Municipal Clinical Hospital
- Issue: Vol 6, No 3 (2011)
- Pages: 50-56
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 23.08.2011
- URL: https://oncohematology.abvpress.ru/ongm/article/view/90
- DOI: https://doi.org/10.17650/1818-8346-2011-6-3-50-56
- ID: 90
Cite item
Full Text
Abstract
Central nervous system (CNS) involvement in advanced non-Hodgkin’s lymphoma (NHL) occurs in 5–29 % of cases. Primary CNS lymphoma (PLCNS) significantly less revealed: 1–2 % of lymphoma cases and 5 % of all malignant CNS diseases. Historically, PLCNS treated with radiotherapy, but the majority of patients had no long-term remission. Combined treatment (chemotherapy + radiation therap y) has been developed to improve radiotherapy efficacy. The research results, according to several authors, allowed to develop the bas is of modern medical approaches, which includes a combination of high-doses methotrexate and cytarabine with radiation therapy for remission consolidation. New drugs — temozolomide, topotecan and rituximab — in combination with conventional preparates have been studied. Treatment results of 11 patients with primary (8) or secondary (3) CNS lymphomas treated in Botkin Municipal Clinical Hospital was analyzed. In 9 from 11 (all with primary lesion) diffuse B-large cell lymphoma w as diagnosed (by immunohistochemistry). All primary patients received 3.5–5 g/m2 methotrexate and 2–4 doses 2 g/m2 cytarabine (except 2 patients); 3 patients in addition received ifosfamide, vincristine and etoposide under a pediatric protocol BFM-90. Subsequently , all patients received 46 Gy cranial irradiation. 75 % of pa tients achieved complete or partial remission. One patient died from infectious complication after 2nd chemotherapy course. 2 patients have early progression. Five patients are alive with follow-up from 6 months to 3.5 years and 4 of them remains in remission. Therapy with methotrexate + cytarabine was accompanied by III–IV grade neutropenia in the majority of patients, but its duration w as not great. The data obtained are consistent with results of modern treatment protocols PLCNS.
About the authors
S. V. Minenko
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Author for correspondence.
Email: svetlanaminenko@yandex.ru
Russian Federation
Yu. V. Larina
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
V. V. Ptushkin
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
N. K. Khuazheva
Botkin Municipal Clinical HospitalRussian Federation
V. V. Lunin
Botkin Municipal Clinical HospitalRussian Federation
T. N. Perestoronina
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
E. R. Biyachuev
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
A. V. Pshonkin
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
S. V. Semochkin
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
Zh. V. Sheikh
Botkin Municipal Clinical HospitalRussian Federation
V. N. Yakovlev
Botkin Municipal Clinical HospitalRussian Federation
V. G. Alekseev
Botkin Municipal Clinical HospitalRussian Federation
References
Supplementary files
